The gene expression signature of anagrelide provides an insight into its mechanism of action and uncovers new regulators of megakaryopoiesis

Summary Background Anagrelide is a cytoreductive agent used to lower platelet counts in essential thrombocythemia. Although the drug has been known to selectively inhibit megakaryopoiesis for many years, the molecular mechanism accounting for this activity is still unclear. Objectives and Methods To...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of thrombosis and haemostasis 2015-06, Vol.13 (6), p.1103-1112
Hauptverfasser:	Ahluwalia, M., Butcher, L., Donovan, H., Killick‐Cole, C., Jones, P. M., Erusalimsky, J. D.
Format:	Artikel
Sprache:	eng
Schlagworte:	activating transcription factor 4 Activating Transcription Factor 4 - genetics Activating Transcription Factor 4 - metabolism anagrelide Cell Cycle Proteins - genetics Cell Cycle Proteins - metabolism Cell Proliferation Cells, Cultured Computational Biology Databases, Genetic Eukaryotic Initiation Factor-2 - genetics Eukaryotic Initiation Factor-2 - metabolism eukaryotic initiation factor‐2, alpha subunit Gene expression Gene Expression Profiling - methods Gene Expression Regulation Gene Regulatory Networks Hematologic Agents - pharmacology Humans megakaryocyte Megakaryocytes - drug effects Megakaryocytes - metabolism Oligonucleotide Array Sequence Analysis Phosphorylation Polymerase Chain Reaction Protein-Serine-Threonine Kinases - antagonists & inhibitors Protein-Serine-Threonine Kinases - genetics Protein-Serine-Threonine Kinases - metabolism Quinazolines - pharmacology Repressor Proteins - genetics Repressor Proteins - metabolism Signal Transduction thrombocytosis Thrombopoiesis - drug effects Thrombopoiesis - genetics Time Factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!